Adicet Bio (ACET) Stock Price

Adicet Bio Price

NASDAQ·CLOSED
6.52
​
Market closed

Revenue at Adicet Bio has contracted by 17.3% per year over the past 14 years to 24.99 M USD. Earnings per share have grown at 8.9% per year over the last 7 years. Adicet Bio's net margin stands at -279.3%, down from -113.7% several years earlier. Adicet Bio currently offers a dividend yield of about 1.15%. Analysts set a median price target of 8.16 USD, implying 25.2% above the current price. Of 14 analysts, 12 rate the stock a buy — an overall Buy consensus.

Adicet Bio stock price

Access this data via the Eulerpool API

Adicet Bio business model & stock analysis

Adicet Bio, Inc. is a biotechnology company which engages in the design and development of off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2018-01-26. The firm is focused on developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is developing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enable selective tumor targeting, facilitate innate and adaptive anti-tumor immune response and improve persistence for durable activity in patients. Its pipeline includes ADI-001, ADI-002 and ADI-00x. ADI-001 is a gamma delta chimeric antigen receptor (CAR)-modified T cell therapy targeting CD20. ADI-002 is a gamma delta T cell containing a CAR that is specific for glypican 3 protein (GPC3). The firm is focused on developing ADI-00x for solid tumors and solid tumor and hematological indications.

Frequently asked questions about Adicet Bio

Analysts currently set an average price target of 7.75 USD for the Adicet Bio stock (median: 8.16 USD), implying +18.9 % versus the latest price. The consensus is based on 14 analyst ratings.

12 analysts currently rate the Adicet Bio stock: 11 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Adicet Bio to generate revenue of 2.86 M USD and earnings per share of -8.86 USD.

Converted at the current exchange rate, the Adicet Bio share trades at 5.80 EUR (6.52 USD).

The Adicet Bio share (ACET) is listed on 6 stock exchanges, including: NASDAQ (ACET), London (0HX7.L), Frankfurt (1IJA.F), München (1IJA.MU), Düsseldorf (1IJA.DU).

The expected revenue of Adicet Bio is 2.86 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Adicet Bio is -61.04 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Adicet Bio is currently -0.74. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Adicet Bio stock.

The price-to-sales ratio (P/S) of Adicet Bio is currently 15.73. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Adicet Bio stock.

The Eulerpool Quality Score for Adicet Bio is 2/10.

The ISIN of Adicet Bio is US0070022076. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Adicet Bio is A2QESQ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Adicet Bio is ACET. The ticker symbol is used to trade Adicet Bio shares on the stock exchange.

Fair ValueTerminal
6.91 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Biotechnology
Number of shares
Employees
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Currency
USD
Initial public offering
Jan 26, 2018
ISIN
US0070022076
Cusip
007002108
Sedol
BMC5RV6
Market capitalization
62.59 M USDMicro Cap
52-Week Range
Revenue growth (10Y) > 5%
Revenue growth (3Y) > 5 %
EBIT growth (10Y) > 5%
EBIT growth (3Y) > 5 %
Net debt < 4x EBIT
Profitable since 10Y+
EBIT Drawdown (10Y) < 50%
Return on Equity (ROE) > 15%
ROCE > 15%
Return Expectation > 10%
PEG
—
P/E ratio
P/Ee 2026
-0.74
P/Ee 2027
-1.16
P/Ee 2028
-5.56
P/Ee 2029
2.77
P/Ee 2030
0.99
P/S
P/Se
15.73
EV/EBIT
0.00
P/B Ratio
0.39
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
-67.15 %
Gross Margin
—
EBIT Margin
—
Net Margin
—
EPS (Earnings Per Share)
-16.95 USD
Net Debt / EBIT
0.52
Debt/Equity
0.09
Last updated Oct 5, 2026, 9:24 PM

Adicet Bio Ticker

DÜSSELDORF · 1IJA.DUFRANKFURT · 1IJA.FLONDON · 0HX7.LLONDON STOCK EXCHANGE · 0HX7.LMUNICH · 1IJA.MUNASDAQ · ACET

All fundamentals and in-depth analysis of Adicet Bio

Our stock analysis for Adicet Bio stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Adicet Bio. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.